Abstract: The present disclosure relates to a ropivacaine suspension injection, and a preparation method therefor. Specifically, the ropivacaine suspension injection of the present disclosure comprises ropivacaine and a pharmaceutically acceptable excipient, wherein the median particle size D50 of the suspension injection is within the range of 1 ?m to 40 ?m. The ropivacaine suspension injection of the present disclosure can continuously release a drug in vivo, and has an analgesic effect of no less than 12 h, preferably, an analgesic effect of no less than 24 h, and more preferably, an analgesic effect of no less than 72 h.

Abstract: An injectable pharmaceutical composition, a preparation method therefor and use thereof are provided. The pharmaceutical composition contains an active ingredient and a pharmaceutically acceptable auxiliary material. The active ingredient comprises cabotegravir or a pharmaceutically acceptable salt thereof, and the auxiliary material comprises a surfactant and a suspending agent. The pharmaceutical composition and a formulation thereof are used for treating and preventing HIV infection, have good stability, and are suitable for industrial production.